Abstract 1465P
Background
Pembrolizumab monotherapy and immune checkpoint inhibitor plus chemotherapy (ICI/Chemo) have been approved as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death ligand 1 tumor proportion score (PD-L1 TPS) ≥50%. However, the clear distinction between the two therapeutic options remains unclear. It was reported that using proton pump inhibitors (PPI) and antibiotics correlated with poorer treatment outcomes of ICI monotherapy for NSCLC.
Methods
We retrospectively enrolled consecutive PD-L1 TPS ≥50% advanced NSCLC patients who received pembrolizumab monotherapy or ICI/Chemo as first-line treatment. We analyzed the association between treatment outcome and patient characteristics, including concomitant drug history in each group. Comparing the treatment outcome, propensity score matching was used to reduce bias.
Results
The study included 425 patients, with 271 receiving pembrolizumab monotherapy and 154 receiving ICI/Chemo. According to the multivariate analysis, a history of PPI usage was independently associated with shorter progression-free survival (PFS) in pembrolizumab monotherapy group(hazard ratio (HR): 1.38, 95.0% CI: 1.00–1.91; P = 0.048), but not in ICI/Chemo group (HR: 0.83, 95.0% CI: 0.48–1.45; P = 0.515). In patients with a history of PPI, both the median PFS (19.3 months vs. 5.7 months, P=0.002) and the median overall survival (OS) (not reached vs. 18.4 months, P=0.025) were significantly longer in ICI/Chemo group than in pembrolizumab monotherapy group. In patients without a history of PPI, the median PFS (18.8 months vs. 10.6 months, P=0.259) and the median OS (not reached vs. 29.9 months, P=0.211) was not significantly different between each group.
Conclusions
History of PPI usage was negatively associated with treatment outcome of pembrolizumab monotherapy, but not ICI/Chemo in NSCLC patients with PD-L1 expression ≥50%. Our observations in real-world settings suggest that the history of PPI usage may be a predictive clinical factor to be considered in treatment decision-making in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20
1433P - CNS efficacy of atezolizumab, bevacizumab, carboplatin and paclitaxel in patients with non-small cell lung cancer and actionable mutations
Presenter: Marcus Rathbone
Session: Poster session 20
1434P - Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy
Presenter: sara arabyarmohammadi
Session: Poster session 20
1435P - Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis
Presenter: Helena Linardou
Session: Poster session 20
1436P - Prospective study utilizing ctDNA genome-wide copy number variations for longitudinal monitoring of patients with advanced non-small cell lung cancer
Presenter: Pengkai Han
Session: Poster session 20
1437P - Clinical and economic burden of tissue re-biopsy (TRB) vs. tissue followed by liquid biopsy (TFLB) in metastatic non-small cell lung cancer (mNSCLC) patients
Presenter: Nicole Engel-Nitz
Session: Poster session 20
1438P - Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
Presenter: Tamta Makharadze
Session: Poster session 20
1440P - Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Presenter: Enriqueta Felip
Session: Poster session 20
1441P - Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Presenter: Francois Ghiringhelli
Session: Poster session 20